Azithromycin News and Research

RSS

Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.

Tianyin Pharmaceutical reports 40.2% increase in revenues for the first quarter of fiscal 2010

Tianyin Pharmaceutical Co., Inc., a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced fiscal results for its first quarter ended September 30, 2009.

13 Nov 2009

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2009, reporting a net loss of $8.5 million or ($0.12) per common share.

5 Nov 2009

Patient enrollment in three late-stage clinical trials completed

Inspire Pharmaceuticals, Inc. announced today patient enrollment is complete in three of its late-stage clinical trials.

5 Nov 2009

Inspire to present its denufosol tetrasodium cystic fibrosis program data at the 23rd NACFC

Inspire Pharmaceuticals, Inc. announced today Inspire scientists and collaborators will present data from the denufosol tetrasodium cystic fibrosis (CF) program in a poster presentation at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) October 15 - 17, 2009 in Minneapolis, MN.

15 Oct 2009

Tianyin Pharmaceutical announces fiscal 2009 financial results

Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today announced Annual 2009 financial results ended June 30, 2009.

24 Sep 2009

AzaSite production increased to combat erythromycin ophthalmic ointment shortage

InSite Vision Incorporated today announced that Inspire Pharmaceuticals, its commercial partner for AzaSite (azithromycin ophthalmic solution) 1% in the U.S and Canada, has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).

15 Sep 2009

Inspire Pharmaceuticals to increase production of azithromycin ophthalmic solution

Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration (FDA) and is increasing its production of AzaSite® (azithromycin ophthalmic solution) 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).

10 Sep 2009

Antibiotic used to treat trachoma reduces child mortality in Ethiopia, study finds

The antibiotic used to treat trachoma, "the world's leading preventable cause of blindness," may also protect children living in Ethiopia from death from of other diseases, according to a recent study, the Associated Press reports.

2 Sep 2009

Eye disease medication lowers death rate among Ethiopian children

Children in Ethiopia who received the antibiotic azithromycin as a method for controlling the contagious eye disease trachoma had a lower odds of death compared to children who did not receive the antibiotic, according to a study in the September 2 issue of JAMA.

2 Sep 2009

Hospira receives FDA approval for Azithromycin for injection

Hospira, Inc has announced it has received U.S. Food and Drug Administration (FDA) approval for a 500 mg vial of azithromycin for injection in the ADD-Vantage System.

30 Jun 2009

Sagent Pharmaceuticals receives FDA approval of Azithromycin for injection

Sagent Pharmaceuticals, Inc. has announced U.S. Food and Drug Administration (FDA) approval of azithromycin for injection, a semi-synthetic, macrolide antibiotic that is used to treat a wide variety of bacterial infections. Sagent will offer azithromycin in a 500 mg vial for intravenous use.

26 Mar 2009

Discovery of better treatment for bacterial pneumonia

Scientists at St. Jude Children's Research Hospital have demonstrated a more effective treatment for bacterial pneumonia following influenza.

9 Jan 2009

Chlamydia treatment in UK pharmacies will deliver convenient care for patients

Today's decision by the Medicines and Healthcare products Regulatory Agency (MHRA) to approve the reclassification of azithromycin for the treatment of chlamydia infection will mean convenient and effective care for patients, said the Royal Pharmaceutical Society of Great Britain (RPSGB).

5 Aug 2008

Chlamydia antibiotic available over-the-counter in the UK

For the first time sufferers in the UK from the common sexually transmitted infection (STI) chlamydia will be able to buy an antibiotic to treat the infection over-the-counter (OTC), without a prescription from a doctor.

5 Aug 2008

New understanding of how some bacteria survive antibiotic treatment

Researchers at the University of Illinois at Chicago have discovered how some bacteria can survive antibiotic treatment by turning on resistance mechanisms when exposed to the drugs.

30 Apr 2008

Rethink needed on how communities affected with trachoma are treated

One or two rounds of high coverage mass treatment with azithromycin, rather than the annual treatment recommended by the World Health Organisation, may be enough to eliminate the eye disease trachoma in communities with moderate levels of infection.

23 Apr 2008

Biannual mass antibiotic treatment may help reduce contagious eye disease trachoma in Africa

Changing the administration of the antibiotic azithromycin from once to twice a year in villages in Ethiopia substantially reduced eye infections in preschool children caused by chlamydia, which causes the serious, contagious eye disease trachoma, according to a study in the February 20 issue of JAMA.

20 Feb 2008

Mylan receives FDA approval for Azithromycin tablets

Mylan Laboratories Inc. ( NYSE:MYL ) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Azithromycin Tablets, 250 mg and 500 mg.

1 Jun 2007

Simple "dipstick" test could save millions from blindness

A Cambridge University team have developed a simple "dipstick" test to detect the eye infection trachoma, a disease spread by flies, which could potentially help save the sight of millions around the world.

15 May 2006

Single dose of oral antibiotic azithromycin taken after trichiasis eye surgery prevents recurrence of inturned eyelashes

A Johns Hopkins Medicine study finds that a single dose of the oral antibiotic azithromycin taken after trichiasis eye surgery can reduce the frequency with which eyelashes turn back in and abrade the eye.

14 Mar 2006